FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308441105> ?p ?o ?g. }

• W4308441105 endingPage "10" @default.
• W4308441105 startingPage "1" @default.
• W4308441105 abstract "COVID-19 symptoms can cause substantial disability, yet no therapy can currently reduce their frequency or duration. We conducted a double-blind placebo-controlled trial of hesperidin 1000 mg once daily for 14 days in 216 symptomatic nonvaccinated COVID-19 subjects. Thirteen symptoms were recorded after 3, 7, 10, and 14 days. The primary endpoint was the proportion of subjects with any of four cardinal (group A) symptoms: fever, cough, shortness of breath, or anosmia. At the baseline, symptoms in decreasing frequency were as follows: cough (53.2%), weakness (44.9%), headache (42.6%), pain (35.2%), sore throat (28.7%), runny nose (26.9%), chills (22.7%), shortness of breath (22.2%), anosmia (18.5%), fever (16.2%), diarrhea (6.9%), nausea/vomiting (6.5%), and irritability/confusion (3.2%). Group A symptoms in the placebo vs. hesperidin group were 88.8% vs. 88.5% (day 1) and reduced to 58.5 vs. 49.4% at day 14 (OR 0.69, 95% CI 0.38-1.27, p = 0.23). At day 14, 15 subjects in the placebo group and 28 in the hesperidin group failed to report their symptoms. In an attrition bias analysis imputing no symptoms to missing values, the hesperidin group showed reduction of 14.5% of group A symptoms from 50.9% to 36.4% (OR: 0.55, 0.32-0.96, p = 0.03). Anosmia, the most frequent persisting symptom (29.3%), was lowered by 7.3% to 25.3% in the hesperidin group vs. 32.6% in the placebo group (p = 0.29). The mean number of symptoms in the placebo and hesperidin groups was 5.10 (SD 2.26) vs. 5.48 (SD 2.35) (day 1) and 1.40 (SD 1.65) vs. 1.38 (SD 1.76) (day 14) (p = 0.92). In conclusion, most nonvaccinated COVID-19 infected subjects remain symptomatic after 14 days with anosmia being the most frequently persisting symptom. Hesperidin 1 g daily may help reduce group A symptoms. Earlier treatment of longer duration and/or higher dosage should be tested." @default.
• W4308441105 created "2022-11-11" @default.
• W4308441105 creator A5010913589 @default.
• W4308441105 creator A5024679356 @default.
• W4308441105 creator A5027401344 @default.
• W4308441105 creator A5037012746 @default.
• W4308441105 creator A5045052502 @default.
• W4308441105 creator A5056970185 @default.
• W4308441105 creator A5064945180 @default.
• W4308441105 creator A5072999020 @default.
• W4308441105 creator A5078082347 @default.
• W4308441105 creator A5085588649 @default.
• W4308441105 creator A5091292268 @default.
• W4308441105 date "2022-11-03" @default.
• W4308441105 modified "2023-10-01" @default.
• W4308441105 title "Fourteen-Day Evolution of COVID-19 Symptoms during the Third Wave in Nonvaccinated Subjects and Effects of Hesperidin Therapy: A Randomized, Double-Blinded, Placebo-Controlled Study" @default.
• W4308441105 cites W1978897742 @default.
• W4308441105 cites W2031034395 @default.
• W4308441105 cites W2096170389 @default.
• W4308441105 cites W2173221344 @default.
• W4308441105 cites W2312937577 @default.
• W4308441105 cites W2373330095 @default.
• W4308441105 cites W2614217133 @default.
• W4308441105 cites W2795524640 @default.
• W4308441105 cites W2913856862 @default.
• W4308441105 cites W2917927916 @default.
• W4308441105 cites W2936340441 @default.
• W4308441105 cites W3001118548 @default.
• W4308441105 cites W3001897055 @default.
• W4308441105 cites W3008142620 @default.
• W4308441105 cites W3009912996 @default.
• W4308441105 cites W3015571324 @default.
• W4308441105 cites W3016010853 @default.
• W4308441105 cites W3016367228 @default.
• W4308441105 cites W3017008398 @default.
• W4308441105 cites W3017287557 @default.
• W4308441105 cites W3033805824 @default.
• W4308441105 cites W3037429853 @default.
• W4308441105 cites W3044231852 @default.
• W4308441105 cites W3048804923 @default.
• W4308441105 cites W3109022689 @default.
• W4308441105 doi "https://doi.org/10.1155/2022/3125662" @default.
• W4308441105 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36387348" @default.
• W4308441105 hasPublicationYear "2022" @default.
• W4308441105 type Work @default.
• W4308441105 citedByCount "7" @default.
• W4308441105 countsByYear W43084411052023 @default.
• W4308441105 crossrefType "journal-article" @default.
• W4308441105 hasAuthorship W4308441105A5010913589 @default.
• W4308441105 hasAuthorship W4308441105A5024679356 @default.
• W4308441105 hasAuthorship W4308441105A5027401344 @default.
• W4308441105 hasAuthorship W4308441105A5037012746 @default.
• W4308441105 hasAuthorship W4308441105A5045052502 @default.
• W4308441105 hasAuthorship W4308441105A5056970185 @default.
• W4308441105 hasAuthorship W4308441105A5064945180 @default.
• W4308441105 hasAuthorship W4308441105A5072999020 @default.
• W4308441105 hasAuthorship W4308441105A5078082347 @default.
• W4308441105 hasAuthorship W4308441105A5085588649 @default.
• W4308441105 hasAuthorship W4308441105A5091292268 @default.
• W4308441105 hasBestOaLocation W43084411051 @default.
• W4308441105 hasConcept C126322002 @default.
• W4308441105 hasConcept C141071460 @default.
• W4308441105 hasConcept C142724271 @default.
• W4308441105 hasConcept C204787440 @default.
• W4308441105 hasConcept C27081682 @default.
• W4308441105 hasConcept C2777844070 @default.
• W4308441105 hasConcept C2777870961 @default.
• W4308441105 hasConcept C2778311950 @default.
• W4308441105 hasConcept C2778573518 @default.
• W4308441105 hasConcept C2778594517 @default.
• W4308441105 hasConcept C2780580376 @default.
• W4308441105 hasConcept C2780852908 @default.
• W4308441105 hasConcept C42219234 @default.
• W4308441105 hasConcept C71924100 @default.
• W4308441105 hasConceptScore W4308441105C126322002 @default.
• W4308441105 hasConceptScore W4308441105C141071460 @default.
• W4308441105 hasConceptScore W4308441105C142724271 @default.
• W4308441105 hasConceptScore W4308441105C204787440 @default.
• W4308441105 hasConceptScore W4308441105C27081682 @default.
• W4308441105 hasConceptScore W4308441105C2777844070 @default.
• W4308441105 hasConceptScore W4308441105C2777870961 @default.
• W4308441105 hasConceptScore W4308441105C2778311950 @default.
• W4308441105 hasConceptScore W4308441105C2778573518 @default.
• W4308441105 hasConceptScore W4308441105C2778594517 @default.
• W4308441105 hasConceptScore W4308441105C2780580376 @default.
• W4308441105 hasConceptScore W4308441105C2780852908 @default.
• W4308441105 hasConceptScore W4308441105C42219234 @default.
• W4308441105 hasConceptScore W4308441105C71924100 @default.
• W4308441105 hasFunder F4320327729 @default.
• W4308441105 hasLocation W43084411051 @default.
• W4308441105 hasLocation W43084411052 @default.
• W4308441105 hasLocation W43084411053 @default.
• W4308441105 hasLocation W43084411054 @default.
• W4308441105 hasOpenAccess W4308441105 @default.
• W4308441105 hasPrimaryLocation W43084411051 @default.
• W4308441105 hasRelatedWork W1525624058 @default.
• W4308441105 hasRelatedWork W1986180015 @default.
• W4308441105 hasRelatedWork W1986578966 @default.

• next